JP2015513309A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513309A5
JP2015513309A5 JP2014546186A JP2014546186A JP2015513309A5 JP 2015513309 A5 JP2015513309 A5 JP 2015513309A5 JP 2014546186 A JP2014546186 A JP 2014546186A JP 2014546186 A JP2014546186 A JP 2014546186A JP 2015513309 A5 JP2015513309 A5 JP 2015513309A5
Authority
JP
Japan
Prior art keywords
dexmedetomidine
metered
pharmaceutically acceptable
acceptable salt
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014546186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513309A (ja
JP6268100B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068988 external-priority patent/WO2013090278A2/en
Publication of JP2015513309A publication Critical patent/JP2015513309A/ja
Publication of JP2015513309A5 publication Critical patent/JP2015513309A5/ja
Application granted granted Critical
Publication of JP6268100B2 publication Critical patent/JP6268100B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014546186A 2011-12-11 2012-12-11 鼻腔内デクスメデトミジン組成物およびその使用方法 Expired - Fee Related JP6268100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569255P 2011-12-11 2011-12-11
US61/569,255 2011-12-11
PCT/US2012/068988 WO2013090278A2 (en) 2011-12-11 2012-12-11 Intranasal dexmedetomidine compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017172633A Division JP6505177B2 (ja) 2011-12-11 2017-09-08 鼻腔内デクスメデトミジン組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2015513309A JP2015513309A (ja) 2015-05-07
JP2015513309A5 true JP2015513309A5 (enExample) 2016-01-21
JP6268100B2 JP6268100B2 (ja) 2018-01-24

Family

ID=48613351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546186A Expired - Fee Related JP6268100B2 (ja) 2011-12-11 2012-12-11 鼻腔内デクスメデトミジン組成物およびその使用方法
JP2017172633A Expired - Fee Related JP6505177B2 (ja) 2011-12-11 2017-09-08 鼻腔内デクスメデトミジン組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017172633A Expired - Fee Related JP6505177B2 (ja) 2011-12-11 2017-09-08 鼻腔内デクスメデトミジン組成物およびその使用方法

Country Status (20)

Country Link
US (2) US9795559B2 (enExample)
EP (2) EP3406247A1 (enExample)
JP (2) JP6268100B2 (enExample)
KR (1) KR102190009B1 (enExample)
CN (1) CN104470516A (enExample)
AU (2) AU2012352528B9 (enExample)
BR (1) BR112014019171A8 (enExample)
CA (1) CA2858721C (enExample)
CL (1) CL2014001515A1 (enExample)
CO (1) CO7000773A2 (enExample)
CR (1) CR20140318A (enExample)
DO (1) DOP2014000123A (enExample)
EC (1) ECSP14007644A (enExample)
IL (1) IL232977B (enExample)
MX (1) MX367286B (enExample)
PE (1) PE20142314A1 (enExample)
PH (1) PH12014501273A1 (enExample)
RU (1) RU2692245C2 (enExample)
SG (2) SG11201403094TA (enExample)
WO (1) WO2013090278A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000609A1 (en) 2010-06-16 2012-01-05 Cargill, Incorporated Starch-based compositions for latex replacement
CN104470516A (zh) 2011-12-11 2015-03-25 瑞克欧制药有限公司 鼻内右美托咪定组合物和其使用方法
ES2904570T3 (es) * 2013-09-24 2022-04-05 Satsuma Pharmaceuticals Inc Formulación de DHE intranasal para el tratamiento del dolor de cabeza
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
WO2015054063A1 (en) * 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
CA3045043A1 (en) 2016-12-31 2018-07-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CN109620802A (zh) * 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CN120284965A (zh) 2018-12-11 2025-07-11 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
CN116474218A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
WO2020259440A1 (zh) * 2019-06-28 2020-12-30 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN113827590A (zh) * 2020-06-08 2021-12-24 四川普锐特药业有限公司 右美托咪定在助眠药物制备中的应用
KR20230136612A (ko) * 2021-01-04 2023-09-26 바이오엑셀 테라퓨틱스 인코포레이티드 덱스메데토미딘 치료 용법
CN115137699B (zh) * 2021-03-29 2024-05-03 四川普锐特药业有限公司 一种增效防腐的右美托咪定鼻喷剂
CN113876776A (zh) * 2021-11-04 2022-01-04 江苏大学附属医院 一种复方鼻喷镇痛药剂及其制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2025176701A1 (en) * 2024-02-19 2025-08-28 Rigshospitalet Novel pediatric composition of nasal dexmedetomidine

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DE122007000103I1 (de) 1990-12-05 2008-04-03 Gen Hospital Corp Verwendung von NO zur Behandlung der persistenten pulmonalen Hypertonie des Neugeborenen
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
WO2000023066A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US5713907A (en) 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
CZ297042B6 (cs) 1996-05-29 2006-08-16 Delsitechoy Dodávkové zarízení pro pomalé uvolnování biologicky úcinného cinidla, jeho pouzití a farmaceutický prostredek s jeho obsahem
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
AUPR184500A0 (en) 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US6582457B2 (en) 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US20030022926A1 (en) 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
EA008829B1 (ru) * 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
EP1986642B1 (en) 2006-02-13 2013-11-13 Orient Pharma (Samoa) Co, Ltd Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2008003093A2 (en) 2006-06-29 2008-01-03 Questcor Pharmaceuticals, Inc. Pharmaceutical compositions and related methods of treatment
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CN101057830A (zh) 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法
MX2010006932A (es) 2007-12-21 2010-10-05 Schering Plough Healthcare Aumento de la fotoestabilizacion de la oximetazolina.
EP2429521B1 (en) * 2009-05-15 2017-10-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
KR20180052610A (ko) * 2009-07-27 2018-05-18 노시셉터 엘엘씨 통증 치료 방법
RU2012133969A (ru) * 2010-01-08 2014-02-20 Рекро Фарма, Инк. Локальные трансдермальные композиции дексмедетомидина и способы их применения
CN104470516A (zh) * 2011-12-11 2015-03-25 瑞克欧制药有限公司 鼻内右美托咪定组合物和其使用方法

Similar Documents

Publication Publication Date Title
JP2015513309A5 (enExample)
RU2014128343A (ru) Интраназальные композиции дексмедетомидина и способы их применения
AR077484A1 (es) Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion
HRP20191805T1 (hr) Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
GB0814302D0 (en) Compounds and methods
MX2011012043A (es) Sistema farmaceutico para suministro transmembrana.
HK1201475A1 (en) Methods and compositions for treating pain
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
ME02662B (me) Niskofrekventna terapija glatiramer acetatom
AU2013305569A1 (en) Composition for the treatment of migraine headaches
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
JP2023532972A (ja) グルココルチコイド節約剤
JP2016505050A5 (enExample)
MX2023005763A (es) Composiciones y metodos para la administracion dermica profunda de farmacos.
Bowe et al. Therapeutic update: acne
EP4460297A1 (en) Intranasal olanzapine formulations and methods of their use
JP7369523B2 (ja) 中等度~重度のインフルエンザの処置
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
RU2010129409A (ru) Способ лечения псороптоза кроликов и отодектоза плотоядных животных
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
CN103458928B (zh) (r)-1,2-丙二醇用作治疗性冷却剂组合物中的溶剂
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.